Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. is actively engaging with investors and showcasing its product pipeline, particularly focusing on its lead candidate TNX-102 SL for fibromyalgia management, with a PDUFA goal date set for August 15, 2025 [1][3]. Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company that develops therapies for pain management and vaccines addressing public health challenges [3]. - The company’s development portfolio emphasizes central nervous system (CNS) disorders, with TNX-102 SL being a priority candidate for fibromyalgia [3]. Product Pipeline - TNX-102 SL has been submitted for NDA based on two statistically significant Phase 3 studies and has received Fast Track designation from the FDA [3]. - The product is also being explored for acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina [3]. - Other notable candidates include TNX-1300 for cocaine intoxication, which has FDA Breakthrough Therapy designation, and TNX-1500 for organ transplant rejection and autoimmune diseases [3]. - Tonix is developing TNX-801, a vaccine for mpox, and has secured a contract with the U.S. Department of Defense for up to $34 million to develop TNX-4200, a broad-spectrum antiviral [3]. Commercial Products - Tonix Medicines, the commercial subsidiary, markets Zembrace SymTouch and Tosymra for the treatment of acute migraine in adults [3].